Bayer to Acquire Cancer Drugmaker Algeta for $2.9 Billion


Dec 19, 2013

After increasing its bid by $500 million, Bayer plans to buy Norwegian drugmaker Algeta, its partner on the prostate-cancer drug Xofigo, for $2.9 billion.

The Board of Directors of Algeta has unanimously decided to recommend acceptance of the offer to its shareholders.

The cash deal would give Bayer full control over the jointly-developed Xofigo, a drug designed to treat prostate cancer patients whose disease has spread to their bones.

Read the Bayer press release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments